Teza Capital Management LLC Sells 10,705 Shares of Repligen Co. (NASDAQ:RGEN)

Teza Capital Management LLC cut its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 78.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,921 shares of the biotechnology company's stock after selling 10,705 shares during the period. Teza Capital Management LLC's holdings in Repligen were worth $420,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of RGEN. Signaturefd LLC raised its position in shares of Repligen by 172.2% in the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 124 shares during the period. Sava Infond d.o.o. acquired a new position in Repligen in the 4th quarter valued at $29,000. Raiffeisen Bank International AG bought a new position in Repligen in the 4th quarter worth $29,000. Itau Unibanco Holding S.A. bought a new position in Repligen in the 4th quarter worth $40,000. Finally, UMB Bank n.a. lifted its position in Repligen by 49.1% during the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock worth $48,000 after acquiring an additional 110 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Repligen

In other news, Director Margaret Pax bought 250 shares of Repligen stock in a transaction dated Monday, March 17th. The shares were bought at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the purchase, the director now owns 1,043 shares of the company's stock, valued at approximately $157,169.67. This trade represents a 31.53% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 1.20% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Wall Street Zen raised Repligen from a "sell" rating to a "hold" rating in a research report on Thursday, May 8th. TD Cowen began coverage on Repligen in a report on Monday, February 10th. They issued a "buy" rating and a $200.00 target price on the stock. Wolfe Research upgraded Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price target for the company in a report on Tuesday, April 29th. Canaccord Genuity Group reduced their price objective on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research report on Wednesday, April 16th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $180.00 target price on shares of Repligen in a research report on Monday, May 5th. Six investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $173.25.

Repligen Stock Performance

Shares of NASDAQ RGEN traded down $2.30 during trading hours on Monday, reaching $118.15. The stock had a trading volume of 615,767 shares, compared to its average volume of 740,875. The company has a market cap of $6.64 billion, a price-to-earnings ratio of -231.67, a PEG ratio of 4.54 and a beta of 1.21. Repligen Co. has a twelve month low of $102.97 and a twelve month high of $182.52. The business's fifty day moving average is $130.28 and its two-hundred day moving average is $144.49. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, topping analysts' consensus estimates of $0.35 by $0.04. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The company had revenue of $169.17 million during the quarter, compared to the consensus estimate of $163.65 million. During the same period last year, the firm earned $0.28 EPS. The firm's revenue for the quarter was up 10.4% compared to the same quarter last year. As a group, research analysts expect that Repligen Co. will post 1.72 EPS for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.